Oxford Nanopore Technolo... Share Discussion Threads

[papillon] 11/4/2024 21:08

How are you doing, bamboo2? Gold on fire. GPM doing very well.

[brucie5] 11/4/2024 19:11

They must have considered the pricing point very carefully. Presumably they want widespread adoption and that's what I take from the comment Re "the beauty of the sequencer".
But there's always a tension between too low and too high: a bit like the Laffer Curve in tax policy.

[magnum opus] 11/4/2024 15:53

"Sequence only $1000" reminds me of Leonard Lord who insisted on selling a world class product (the mini) for £400 which was less than cost price, really the machines seem to be very under priced considering PACBIO machines are $0.5m, when will the shareholders get back the hundreds of millions they sunk in returned as dividends when they sell the machines for $1000, so far the co has run up hundred of millions in losses, so I'm thinking really more of these costs should be paid in the price, would make sense to me.

[bamboo2] 11/4/2024 13:28

Just watching Jonathon Edgeworth on webinar

A few notes.

JE only does research work now, no clinical. Works part time for ONT.
Opportunity, infectious, Sepsis, pneumonia, pandemics, Bio security,

Covid drove things forward.
Metagenomics. Beauty of nanopore is sequencer only $1000
Report on pathogen after 2hrs. Culture typically 48-72 hrs

Now doing daily sequencing runs. No errors.
Preventing AMR. In half the cases antibiotic prescription changed.

Loads of q's for the q&a.

With regard to prescribing, Metagenomic testing massively reduces the decision making process, and excludes guesswork. Should become routine for all cases.

q&a

Future, cost effective use elsewhere other than ICU? Yes, needs to be widely deployed. Bio engineering is rapidly progressing. There needs to be a willingness to change. Installation is ongoing at other NHS hospitals as the trial expands.

[bamboo2] 11/4/2024 13:26

2 April 2024

An evolution of Nanopore next-generation sequencing technology: implications for medical microbiology and public health

Next-generation sequencing has evolved as a powerful tool, with applications that extend from diagnosis to public health surveillance and outbreak investigations. Short-read sequencing, using primarily Illumina chemistry, has been the prevailing approach. Single-molecule sensing and long-read sequencing using Oxford Nanopore Technologies (ONT) has witnessed a breakthrough in the evolution of the technology, performance, and applications in the past few years. In this issue of the Journal of Clinical Microbiology, Bogaerts et al. (hxxps://doi.org/10.1128/jcm.01576-23) describe the utility of the latest ONT sequencing technology, the R10.4.1, in bacterial outbreak investigations. The authors demonstrate that ONT R10.4.1 technology can be comparable to Illumina sequencing for single-nucleotide polymorphism-based phylogeny. The authors emphasize that the reproducibility between ONT and Illumina technologies could facilitate collaborations among laboratories utilizing different sequencing platforms for outbreak investigations.

[ih_828197] 11/4/2024 12:51

i just hope they don't get bought for cheap like 1-2B as i can see a future where they make that much in a quarter.

[ih_828197] 11/4/2024 12:48

i'll just keep averaging down or up if the price starts to pick up, like you said i don't see anything wrong fundamentally. If i were you i wouldn't worry too much about finding the perfect entry point as long as you have a long term view (5+ years)that of course changes if you are looking for a swing trade. Actually i'm happy to see the stock price going down means i can buy more for less. There are so many signs that point to nanopore having a clear technological advantage. It's just a question of execution.
I don't think people who bought AMD at 10$ are upset they dind't buy it at 7$ instead ahahah

[brucie5] 11/4/2024 09:35

Anyone else thinking of buying hereabouts? The decline feels curiously like gravitational pull towards £1. Maybe it will then test buyers by further weakening with 90p as base level? Obviously it won't be humble pis who move in to reverse the price, so I'm alert to any large insti buying.
We can't be too far away now and confidence seems to have completely evaporated.
In the meantime I can't see anything wrong with the story. Maybe the market is preparing it for an opportunistic TO?
Brexit Britain : everything bar the crown jewels for sale, and these look like being the jewels in their sector.

[magnum opus] 08/4/2024 09:59

Hard to believe share price now less than half what trade buyer Bio Meriuex paid (238p) back in Oct, mkt cap 950m cash 470m, would seem to be an ideal fit for them because they could sell the devices through their own sales force cutting costs, and use the devices potentially in a lot of new assay methods and approaches, roll on lat expiry in June

[brucie5] 03/4/2024 16:08

I'm waiting for aries to come under the influence of venus in the third solar quadrant of the planetry makeitupasyouwantittarium.
;)
In the absence of which, I might take £1.

[p1nkfish] 02/4/2024 20:31

I'm waiting to see a bullish engulfing candle at decent volume.

[brucie5] 02/4/2024 19:25

I'm waiting for £1.

[p1nkfish] 02/4/2024 10:03

Timing for reversal?

[p1nkfish] 02/4/2024 10:01

Yes, find out soon. Lots of shuffling going on. Possibly a bit of a relief bounce and some further consolidation before a reversal.

[bamboo2] 02/4/2024 08:52

p1nk, I guess we now get to see if the end of year tax loss idea will reduce the number of sellers?

[bamboo2] 29/3/2024 09:04

GIC Private Limited Singapore. Singapore SWF.

Reducing to less than 3%, below both international and UK [TR-1] reporting threshold.

Prior holding was 3.976561% or 34,177,560

=============

I note from INOV's figures to December 31 2023 released this week, that, to the reporting date, their piecemeal disposals of ONT shares had slowed. There didn't appear to be any update on their holding over the past three months of 2024.

[74tom] 28/3/2024 19:33

So in the 2 months since the start if Feb, GIC have disposed of ~8m shares. Fairly obvious why shares are trading at all time lows

[brucie5] 27/3/2024 09:59

Just another 20% to drop, by the looks of.
😏

[brucie5] 25/3/2024 16:38

Blimey. New low. Not far to go now?

[p1nkfish] 24/3/2024 10:42

Tax losses might be a thing too. Crystallising those for use elsewhere.

[bamboo2] 24/3/2024 10:37

Brucie, hope the share price stabilizes soon!

We have at least one seller, INOV, [with the dregs of the former Woodford Patient Capital holding] they report 28/3/2024, so we will get more idea of their position.

GIC, the sovereign wealth fund of Singapore, was also selling recently.
[02/02/2024 TR-1 reduced to 3.976561% or 34,177,560]

Unfortunately many of the international institutional holders are below the 5% reporting threshold, meaning it's hard to keep tabs.

Ironically, the larger holders of shares that were fighting to get their allotments during the flotation now seem content to sell at any price!

This is despite the fact that the intended growth led objectives of the flotation, such as increases in headcount, and accuracy improvements are nearing completion.

[brucie5] 23/3/2024 12:39

Bamboo thank you. I. for one, am most appreciative of your ongoing commentary and undoubted expertise here. It's far too complex for me to understand in any detail, so you help me to see the wood for the trees.

I am looking for a bottoming pattern of the kind I believe we are currently seeing at OXB; and I suspect it won't be until we descend to the £1 level like a plane coming down to land. There may be bumps but eventually I expect a round of applause from the passengers who remained seated.
;)

[bamboo2] 23/3/2024 12:01

Price action is far from ideal.

This is a weak sector at present. Hopefully it should change at some point, as massive expansion of sequencing around the world is forecast. The UK market is discounting many growth and tech stocks, and analysts have taken against ONT management and their attempts to be realistic in the face of unexpected problems, such as the ban on export of devices containing NVDA chips to China.

On the positive side, ONT has almost completed the planned increases of staff in technical, manufacturing and sales functions. Naturally, this should increase turnover. Accuracy continues to improve and customer sentiment is at all time highs. The new ASIC should get an airing in May 2024.

Management have so far made no attempt to extend the life of LAT shares that expire in June 2024, which means takeover potential could lift the valuation. There are a large number of organisations around the world that could currently buy the whole company for pocket money.

I find ONT one of the most exciting companies in the UK, and despite a losing position at present will continue to hold for the long term.

[takeiteasy] 23/3/2024 11:08

Brucie, not just ONT, this part of biotech is in a major downtrend..including the highest beta type stocks in the ARK genomics fund...hot happy 5 year charts at all :(

dyor etc